BofA Raises its Price Target on Teva Pharmaceutical (TEVA) to $42

On March 30, 2026, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced that its applications for a projected biosimilar to Xolair, oromalizumab, person been accepted for reappraisal by some the U.S. FDA and the European Medicines Agency. The filings see a Biologics License Application and a Marketing Authorization Application and screen each approved indications of the notation product, including moderate-to-severe persistent allergic asthma.

Pixabay/Public Domain

On the aforesaid day, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced FDA support of Ponlimsi arsenic a biosimilar to Prolia. The institution said the support covers each indications of the notation product, including attraction of postmenopausal women with osteoporosis astatine precocious hazard for fracture, supported by information showing comparable efficacy, safety, and immunogenicity.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops and markets generic and biopharmaceutical medicines globally.

While we admit the imaginable of TEVA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.